

This is the html version of the file <http://www.fda.gov/ohrms/dockets/dailys/03/Sept03/090203/75N-0183H-emc-000012-01.doc>.

Google automatically generates html versions of documents as we crawl the web.

To link to or bookmark this page, use the following url: <http://www.google.com/search?q=cache:bUL4ySo0cXAJ:www.fda.gov/ohrms/dockets/dailys/03/Sept03/090203/75N-0183H-emc-000012-01.doc+benzethonium+replace+benzalkonium+low+toxicity+formulation&hl=en&gl=us&ct=clnk&cd=1>

Google is neither affiliated with the authors of this page nor responsible for its content.

These search terms have been highlighted: **benzethonium benzalkonium low toxicity formulation**

These terms only appear in links pointing to this page: **replace**

August 27, 2003

Dockets Management Branch

Food and Drug Administration (HFA-305)

5630 Fishers Lane, Room 1061

Rockville, MD 20852

Re: Proposed Rule; Reopening of the Administrative Record for Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Health-Care Antiseptic Drug Products. 68 Fed. Reg. 32003. (May 29, 2003). [Docket No. 75N-183H]

Dear Sir/Madam:

GOJO Industries, Inc. hereby submits these comments in response to the Food and Drug Administration's (FDA's) reopening of the administrative record regarding the tentative final monograph for Over-the-Counter (OTC) Health-Care Antiseptic Drug Products, 59 Fed. Reg. 31402 (June 17, 1994) (1994 TFM). **These comments address the safety and efficacy of benzalkonium chloride and benzethonium chloride as active antimicrobial agents in leave-on products (products used without water and that are not rinsed off the skin).**

SUMMARY:

The anticipated finalization of the 1994 TFM will be accompanied by a review of the safety and efficacy of the quaternary ammonium compounds (quats), ~~benzalkonium chloride and benzethonium chloride~~. These active ingredients are listed as Category III drugs (available data are insufficient to classify as safe and effective, and further testing is required) in the 1994 TFM. We submit that **benzalkonium chloride and benzethonium chloride** lack sufficient data to be classified as safe and effective when specifically used in leave-on (no rinse) products according to the 1994 TFM.

We assert that:

<http://64.233.161.104/search?q=cache:bUL4ySo0cXAJ:www.fda.gov/ohrms/dockets/dailys...> 8/8/06

- **Insufficient scientific evidence exists to approve either benzalkonium chloride or benzethonium chloride as Category I active ingredients for use in leave-on (non rinse) products in the 1994 TFM hand antiseptic categories.**
- **FDA should limit the use of benzalkonium chloride and benzethonium chloride for hand antiseptic use to only those products that are rinsed off the skin until such time as an extensive body of long term scientific evidence exists to demonstrate safety and effectiveness in non rinse, leave-on products.**

The potential for development of bacterial resistance, sensitization, irritation and other untoward effects due to the use of **benzalkonium** chloride and **benzethonium** chloride in leave-on products has been insufficiently addressed. The cumulative safety of these actives for leave-on antiseptic products requires additional scrutiny due to a use pattern that allows unlimited daily use for the lifetime of a user at home, at work and in the health care setting. An important point of reference is topical First Aid products. A survey conducted by Voss and Widmer (1997) suggested that nurses should wash 200 to 300 times per week. Based upon this use frequency, we estimate that nurses using quat containing, no rinse products would be exposed to 100 to 600 grams of quat per week, whereas a first aid antiseptic user would be exposed to approximately 10 to 40 grams of quat per week. In addition, leave-on products may expose the user to a higher initial concentration of the active and for an extended time. Finally, the potential for unchecked use and proliferation of these actives in leave-on products in the consumer market (as is already occurring) further multiplies the potential safety risks. The cumulative exposure to these actives across all applications and use patterns requires in-depth consideration by FDA.

BACKGROUND:

FDA has previously recognized limitations for the use of **benzalkonium** chloride and **benzethonium** chloride. Although quats have been briefly mentioned in several proposed monographs, the use of **benzalkonium** chloride and **benzethonium** chloride has not been granted Category I (generally recognized as safe and effective) status in any final OTC rule. Both have been proposed for Category I status in the tentative First Aid Antiseptic Monograph (FR 56 (140):33644-33680, July 22, 1991) (1991 TFM). However, FDA mandated critical limits on the duration of use (i.e. 7 days), the frequency of use (e.g. one to three times per day), and the size of the treatment area (i.e. small cuts and scrapes). These limitations are not required by the 1994 TFM. The use range of 0.1% to 0.13% **benzalkonium** chloride and 0.1% to 0.2% **benzethonium** chloride has been drawn from this 1991 TFM, although the 1994 TFM does not clearly specify a range. Due to the aforementioned controlled use of quats in First Aid products, FDA should not rely upon the historical experience of First Aid products, as it clearly does not adequately simulate the dose or usage patterns of the 1994 TFM. This approved use pattern represents but a fraction of the exposure that could come from unrestricted, repeated daily use of a quat-based leave-on antiseptic.

FDA has previously recognized the paucity of data on file for **benzalkonium** chloride and **benzethonium** chloride, and in fact, recently requested additional absorption and systemic **toxicity** data in rodent and non-rodent species, skin wound repair comparison, contact dermatitis, and skin sensitization studies. Furthermore, there are insufficient data in the public domain to support the use of these actives in an unlimited, high-frequency use pattern which involves a direct leave-on application.

IRRITATION / SENSITIZATION:

The attached references reveal the potential for irritation, sensitization and allergic response resulting from the use of **benzalkonium** chloride and other quaternary ammonium chlorides. A five-year study of healthcare workers showed a significant difference in dermatitis resulting from exposure to **benzalkonium** chloride compared to non-healthcare workers ($p=0.046$) (Shaffer et al. 2000). In addition, quaternary ammonium chlorides have demonstrated potential for inhibition of wound healing and tissue injury when used as antiseptics (Branemark, 1966, 1967). Prolonged exposure to these actives due to direct "leave-on" application may increase exposure, and thus health effects, as much as ten-fold.

The 2002 Cosmetic Ingredient Review (CIR) Compendium considers **benzalkonium** chloride "cosmetic" formulations above 0.1% to be unsafe; thus the 1994 TFM formulation ranges are inconsistent with more recent

national safety guidelines. Although less safety and efficacy information exists for **benzethonium** chloride, the 2002 CIR Compendium lists **benzethonium** chloride formulations as safe for use in cosmetics at or below 0.5%. Based upon the CIR, **benzethonium** chloride formulations above 0.5% would not be safe for use on human skin. However, the Cosmetic Ingredient Review has listed the **benzethonium** chloride group as requiring re-evaluation due to the age of the submitted studies (early 1980s). As the CIR review was based upon the application of cosmetics, 1994 TFM use patterns would most likely necessitate further reductions in the CIR cut-off values. **Benzalkonium chloride and benzethonium chloride have not been proven safe and effective for use in leave-on products under the extensive use scenario covered by the 1994 TFM. Current 1994 TFM concentration ranges for benzalkonium chloride are unsafe according to the 2002 CIR Compendium.**

ANTIMICROBIAL EFFECTIVENESS:

The efficacy of quaternary ammonium compounds may be severely compromised during formulation and use. **Benzalkonium** chloride and **benzethonium** chloride may be neutralized by anionic or nonionic surfactants, hard water, proteins and other moieties. Special expertise is required when formulating to avoid neutralization of these active ingredients and to carefully balance the need for fast, broad spectrum antimicrobial activity with low irritation. Little published data exist to demonstrate the effectiveness, according to 1994 TFM testing standards, of leave-on formulations based on **benzalkonium** and **benzethonium** chloride across the proposed concentration range. **Thus, we conclude that benzalkonium and benzethonium chloride have not been proven to be generally recognized as effective for use in leave-on products in the future monograph.**

MICROBIAL SKIN FLORA

Published scientific studies have identified concerns for the selection and proliferation of quat-resistant bacteria and accompanying antibiotic cross-resistance (Adair, 1969, 1971; Gilbert, 2003; Joynson, 2002; Loughlin, 2002). Although these studies are mainly laboratory evaluations, many key thought leaders have begun to express concern over these findings. A.D. Russell, the lead academician in this field, stated as early as 1998, "Extensive use of cationic biocides [**benzalkonium** chloride and **benzethonium** chloride] could lead to the selection of staphylococcal strains showing resistance to both antibiotics and biocides..." (Russell, 1998). No studies have been published to date exploring the short or long term impact of the use of **benzalkonium** chloride and **benzethonium** chloride on the ecology of the skin flora and the resistance profiles of its members. Horn's and Larson's elucidations of the changes in the ecology of the skin flora of healthcare workers further emphasize the concern that increased use of **benzalkonium** chloride and **benzethonium** chloride may contribute to a shift in resident skin flora, specifically selecting for Gram negative strains due to the unique innate resistance of these strains to quat compounds or biocide/antibiotic resistant *Staphylococci* (Horn, 1988; Larson, 1998). **Benzalkonium and benzethonium chloride should not be approved as Category I active ingredients for unlimited, high-frequency use in leave-on products until further investigation elucidates their potential to alter the ecology as well as the biocide and antibiotic resistance profiles of human skin flora.**

In summary, FDA should not approve benzalkonium chloride and benzethonium chloride as Category I active ingredients for use in leave-on products in the future antiseptic monograph. Benzalkonium and benzethonium chloride have not been proven safe and effective for use in leave-on products. FDA should limit the use of benzalkonium and benzethonium chloride for antiseptic use to rinse-off products until an extensive body of long term scientific evidence exists to demonstrate safety and effectiveness for leave-on products.

Respectfully Submitted,

GOJO INDUSTRIES, INC.

Michael J. Dolan

Research and Development Vice President

REFERENCES

2002 CIR Compendium. Cosmetic Ingredient Review. 2002; Washington, D.C.

Adair FW, Geftic SG, Gelzer J. Resistance of *Pseudomonas* to Quaternary Ammonium Compounds: I. Growth in **Benzalkonium** Chloride Solution. *Applied Microbiology*. 1969; 18: 299-302.

Adair FW, Geftic SG, Gelzer J. Resistance of *Pseudomonas* to Quaternary Ammonium Compounds: II. Cross-Resistance Characteristics of a Mutant of *Pseudomonas aeruginosa*. *Applied Microbiology*. 1971; 21: 1058-1063.

Aetna IntelliHealth. Skin and Chemical Allergies. Available at <http://www.intelihealth.com/IH/ih/IH/WSIHW000/7945/8215/20816.html?d=dmTJHE>. Accessed July 14, 2003.

Branemark P-I, Albrektsson B, Lindstrom J, Lundborg G. Local Tissue Effects of Wound Disinfectants. *Acta Chir Scand Suppl*. 1966; 357: 166-76.

Branemark P-I, Ekholm R, Albrektsson B, Lindstrom J, Lundborg G, Lundskog J. Tissue Injury Caused by Wound Disinfectants. *The Journal of Bone and Joint Surgery*. 1967; 49: 48-62.

Burdon DW, Whitby JL. Contamination of Hospital Disinfectants with *Pseudomonas* Species. *Brit. Med. J*. 1967; 2: 153-155.

Cosmetic Ingredient Review. Ingredient Review Priorities. Available at <http://www.cir-safety.org/priorities.shtml>. Accessed August 20, 2003.

The Cosmetic, Toiletry, and Fragrance Association. Compilation of Safety Data and Activities of Active Ingredient Suppliers. 2001.

De Groot AC, Conemans J, Liem DH. Contact allergy to benzoxonium chloride (Bradophen®). *Contact Dermatitis*. 1984; 11: 324-325.

Díaz-Ramón L, Aguirre A, Ratón-Nieto JA, de Miguel M. Contact dermatitis from benzoxonium chloride. *Contact Dermatitis*. 1999; 41: 53-54.

Fisher AA, Stillman MA. Allergic Contact Sensitivity to **Benzalkonium** Chloride. *Arch Derm*. 1972; 106: 169-171.

The Food and Drug Administration. Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for First Aid Antiseptic Drug Products; Notice of Proposed Rulemaking. *Federal Register*. July 22, 1991. 56(140):33644-33680.

The Food and Drug Administration. Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products; Notice of Proposed Rulemaking. *Federal Register*. June 17, 1994. 59(116):31402-31452.

Fraki JE, Kalimo K, Tuohimaa P, Aantaa E. Contact Allergy to Various Components of Topical Preparations for Treatment of External Otitis. *Acta Otolaryngol (Stockh)*. 1985; 100: 414-418.

Gilbert P, McBain AJ. Potential Impact of Increased Use of Biocides in Consumer Products on Prevalence of Antibiotic Resistance. *Clinical Microbiology Reviews*. 2003; 16: 189-208.

Henderson ND. A Review of the Environmental Impact and Toxic Effects of DDAC. June, 1992.

<http://64.233.161.104/search?q=cache:bUL4ySo0cXAJ:www.fda.gov/ohrms/dockets/dailys...> 8/8/06

Horn WA, Larson EL, McGinley KJ, Leyden JJ. Microbial Flora on the Hands of Health Care Personnel: Differences in Composition and Antibacterial Resistance. *Infection Control and Hospital Epidemiology*. 1988; 9: 189-193.

Huriez C, Agache P, Martin P, Vandamme G, Mennequier J. L'Allergie Aux Sels D'Ammonium Quaternaire. *Sem Hop*. 1965; 41: 2301-2304.

Huriez C, Agache P, Martin P, Vandamme G, Mennequier J. Un Groupe D'Allergènes Chimiques Fréquemment en Cause: Les Sels D'ammonium Quaternaire. *Rev Fr Allergol*. 1965; 5: 134-142.

Jones MV, Herd TM, Christie HJ. Resistance of *Pseudomonas aeruginosa* to amphoteric and quaternary ammonium biocides. *Microbios*. 1989; 58: 49-61.

Joynson JA, Forbes B, Lambert RJW. Adaptive resistance to **benzalkonium** chloride, amikacin and tobramycin: the effect on susceptibility to other antimicrobials. *Journal of Applied Microbiology*. 2002; 93: 96-107.

Kaslow RA, Mackel DC, Mallison GF. Nosocomial Pseudobacteremia: Positive Blood Cultures Due to Contaminated **Benzalkonium** Antiseptic. *JAMA*. 1976; 236: 2407-2409.

Kanerva L, Jolanki R, Estlander T. Occupational allergic contact dermatitis from **benzalkonium** chloride. *Contact Dermatitis*. 2000; 42: 357-358.

Larson EL, Norton Hughes CA, Pyrek JD, Sparks SM, Cagatay EU, Bartkus JM. Changes in bacterial flora associated with skin damage on hands of health care personnel. *American Journal of Infection Control*. 1998; 26: 513-521.

Lee JC, Fialkow PJ. **Benzalkonium** Chloride – Source of Hospital Infection with Gram-Negative Bacteria. *JAMA*. 1961; 177: 144-146.

Lee JY-Y, Wang B-J. Contact dermatitis caused by cetrimide in antiseptics. *Contact Dermatitis*. 1995; 33: 168-171.

Loughlin MF, Jones MV, Lambert PA. *Pseudomonas aeruginosa* cells adapted to **benzalkonium** chloride show resistance to other membrane-active agents but not to clinically relevant antibiotics. *Journal of Antimicrobial Chemotherapy*. 2002; 49: 631-639.

Maibach HI, Mathias CT. Vulvar dermatitis and fissures – irritant dermatitis from methyl **benzethonium** chloride. *Contact Dermatitis*. 1985; 13): 340.

Placucci F, Benini A, Guerra L, Tosti A. Occupational allergic contact dermatitis from disinfectant wipes used in dentistry. *Contact Dermatitis*. 1996; 35: 306.

Russell AD. Possible link between bacterial resistance and use of antibiotic and biocides. *Antimicrobial Agents and Chemotherapy*. 1998; 42:2151.

Russell AD. Biocides and pharmacologically active drugs as residues and in the environment: Is there a correlation with antibiotic resistance? *AJIC*. 2002; 30: 495-498.

Russell AD. Mechanisms of Antimicrobial Action of Antiseptics and Disinfectants: An Increasingly Important Area of Investigation. *Journal of Antimicrobial Chemotherapy*. 2002; 49: 597-599.

Schnuch A, Geier J, Uter W, Frosch PJ. Patch testing with preservatives, antimicrobials and industrial biocides. Results from a multicentre study. *British Journal of Dermatology*. 1998; 138: 467-476.

Scientific Committee on Cosmetic Products and Non-Food Products. Opinion of the Scientific Committee on

Cosmetic Products and Non-Food Products Intended for Consumers concerning **Benzethonium** Chloride. 2002.

Shaffer MP, Belsito DV. ACD to Glutaraldehyde in Health Care Workers. Presented at the 11th Annual Meeting of the American Dermatitis Society. March 9, 2000. San Francisco, CA.

Shmunes E, Levy EJ. Quaternary Ammonium Compound Contact Dermatitis From a Deodorant. Arch Derm. 1972; 105: 91-93.

Toxicology / Regulatory Services. Overview and Summary of the ADBAC Data Development Program. April 30, 1995.

Voss A, Widmer F. No Time for Handwashing!? Handwashing Versus Alcoholic Rub: Can We Afford 100% Compliance? Infection Control and Hospital Epidemiology. 1997; 18: 205-208.